Table 3. Subgroup analysis according to the initial BMI and HbA1c.
| Baseline | After treatment | P value | |
|---|---|---|---|
| BMI <23 (n=13) | |||
| Total AUC (I/G) | 11.26±2.43 | 17.52±3.12 | 0.034 |
| HOMA-IR | 1.78±0.42 | 2.24±0.42 | 0.116 |
| Matsuda index | 7.96±1.46 | 5.27±0.73 | 0.152 |
| Insulinogenic index | 0.83±0.16 | 1.46±0.48 | 0.082 |
| HOMA-β | 26.46±4.29 | 36.86±4.44 | 0.046 |
| HbA1c, % | 6.57±0.26 | 6.38±0.13 | 0.357 |
| BMI ≥23 (n=11) | |||
| Total AUC (I/G) | 7.51±1.51 | 11.26±2.26 | 0.007 |
| HOMA-IR | 3.96±0.49a | 4.09±1.43 | 0.594 |
| Matsuda index | 4.49±0.98a | 5.15±1.38 | 0.929 |
| Insulinogenic index | 0.49±0.13a | 0.83±0.15 | 0.005 |
| HOMA-β | 27.52±5.38 | 29.67±7.45 | 0.689 |
| HbA1c, % | 7.98±0.36a | 7.64±0.31 | 0.166 |
| HbA1c <7% (53 mmol/mol) (n=11) | |||
| Total AUC (I/G) | 12.51±2.64 | 17.52±1.89 | 0.092 |
| HOMA-IR | 1.70±0.34 | 2.28±0.49 | 0.075 |
| Matsuda index | 7.13±1.09 | 5.40±0.84 | 0.110 |
| Insulinogenic index | 0.83±0.19 | 1.11±0.17 | 0.152 |
| HOMA-β | 33.66±5.24 | 42.69±6.68 | 0.110 |
| HbA1c, % | 6.19±0.15 | 6.27±0.14 | 0.722 |
| HbA1c ≥7% (53 mmol/mol) (n=13) | |||
| Total AUC (I/G) | 6.26±1.04a | 12.51±3.11 | 0.003 |
| HOMA-IR | 3.69±0.55a | 3.77±1.22 | 0.463 |
| Matsuda index | 5.73±1.54 | 5.06±1.17 | 0.972 |
| Insulinogenic index | 0.56±0.14 | 1.25±0.50 | 0.003 |
| HOMA-β | 21.26±3.69a | 25.85±4.31 | 0.294 |
| HbA1c, % | 8.08±0.29a | 7.54±0.27 | 0.031 |
Values are presented as mean±standard error.
BMI, body mass index; AUC (I/G), area under the curve (insulin/glucose); HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; HbA1c, glycosylated hemoglobin.
aDenotes P<0.05 compared with the baseline value of patients in BMI <23 or HbA1c <7% subgroup.